About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, February 7th, 2018

The QualityStocks
Daily Stock List


Cannabis Sativa, Inc. (CBDS)

Flagler Financial Group, Promotion Stock Secrets, Jason Bond, Marketbeat, TopPennyStockMovers, Stockgoodies, Cannabis Financial Network News, Greenbackers, TheMicrocapNews, TopStockAnalysts, Top Pros’ Top Picks, Insider Financial, Darwin Investing Network, Wall Street Mover, Stock Beast, smartOTC, and Real Pennies reported previously on Cannabis Sativa, Inc. (CBDS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Cannabis Sativa, Inc. engages in branding and licensing via its 'hi' intellectual properties. The Company engages, through its subsidiaries, Wild Earth Naturals and "hi" Brands International, Inc., in the research, development, and licensing of specialized natural products. These include formulas, edibles, topicals, recipes, and also delivery systems. Cannabis Sativa has been active in pursuing Intellectual Property (IP) and has successfully acquired an increasing portfolio of IP. Cannabis Sativa is headquartered in Mesquite, Nevada.

Cannabis Sativa’s goal is to license the "hi" brand to distributors and producers of quality products and to other ancillary participants in the retail cannabis industry. The Company brands, licenses, innovates, and markets first-class plant-derived topical creams, transdermals, balms, sublinguals, lubricants, and edibles for medical and recreational marijuana consumers, and legal nutraceuticals and branded merchandise for consumers in general.

Cannabis Sativa has its Wild Earth Naturals offerings. The Company offers the Wild Earth Naturals line of CBD Water and cosmetic products designed to use organic and natural ingredients. These include CBD and hemp seed oil.

Cannabis Sativa’s wholly-owned subsidiary, Hi Brands International, entered into an agreement with Centuria Natural Foods, Inc. to market their proprietary CBD Rich Hemp Oil products. Their CBD capsules are marketed under the name, "hi CBD."

The Company has acquired a majority ownership interest in iBudtender, Inc., a Colorado corporation. Also, it entered into an agreement to acquire a 49 percent ownership interest in a nine-acre property in Los Angeles County, California.

The ownership group’s plan is to lease the property to an industrial hemp farm operator. The operator will conduct farming activities under the Industrial Hemp provisions of California's Adult Use Marijuana Act (Prop 64).

Cannabis Sativa entered into a license agreement for the manufacture, marketing, and sale of its White Rabbit products in California. The Company closed its acquisition of the White Rabbit brand of cannabis sprays and cannabis mints. This acquisition includes the exclusive and proprietary product formulations, product mixes, manufacturing methods, and branding.

The White Rabbit product line now comprises fast-acting low dose cannabis oral sprays and low dose cannabis mints. Cannabis Sativa has developed a "hi" branded infused honey product (hi honey) made from rich African honey and infused with CBD or THC.

Cannabis Sativa acquired a controlling interest in PrestoCorp (a.k.a. PrestoDoctor). This is an online telemedicine platform. It provides access to knowledgeable physicians for a safe and confidential way to get a medical marijuana recommendation using secure video conferencing technology.

This past December, Cannabis Sativa announced that its PrestoDoctor subsidiary is expanding its online medical marijuana recommendation services into New York. At present, PrestoDoctor serves patients through its online platform and with dispensary kiosks operating in California and Nevada. It will now extend its online services to patients located in New York State.

Cannabis Sativa looks for strategic partners for acquisition of operating companies, intellectual property (IP) and other assets that fit within its corporate vision. Furthermore, the Company holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, as well as owns patent pending and trade secret formulas and processes.

Cannabis Sativa, Inc. (CBDS), closed Wednesday's trading session at $6.03, up 13.13%, on 179,063 volume with 520 trades. The average volume for the last 60 days is 215,821 and the stock's 52-week low/high is $2.61/$9.74.

Delta International Oil & Gas, Inc. (DLTZ)

OTC Markets, Speculating Stocks, and MarketWatch reported on Delta International Oil & Gas, Inc. (DLTZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Delta International Oil & Gas, Inc. is an international, independent oil and gas company specializing in energy. Until recently, its main concentration was on oil and gas exploration in northern Argentina via its subsidiary SAHF, LLC. In 2017, upon an evaluation of the U.S. domestic E&P market, it decided to focus its investments locally.

Delta International Oil & Gas is headquartered in Scottsdale, Arizona. The Company previously went by the name Delta Mutual, Inc. It changed its name to Delta International Oil & Gas Inc. in October of 2013. The Company’s shares trade on the OTC Markets’ OTCQB.

The Company’s investment in MHD Technology Corp. helps extend its reach in the energy field. MHD Technology is a New York company that works to apply its patented technology in MagnetoHydroDynamics to water pipelines in the continental U.S.

Delta International Oil & Gas is evaluating prospects for investments in fields other than oil and gas exploration and production. The Company previously announced its acquisition of a 10 percent interest in MHD Technology Corp. by way of its wholly-owned subsidiary Neptune Industries LLC.

MHD Technology is developing an inventive water transportation and desalination technology. MHD's next steps are to perform a simulation of its product and then to make the initial prototype. Delta's subsidiary, Neptune Industries, will initially be involved in both steps, as well as in some administrative capacity.

As of March 31, 2016, Delta International Oil & Gas, via South American Hedge Fund LLC (SAHF), retained 18 percent of the total concession in the carryover mode (no cost obligations to SAHF) in the Tartagal and Morillo oil and gas concessions in Northern Argentina. The Company does not operate the Tartagal and Morillo concession. It has a minority position in the JV.

In addition, Delta holds a 30.6 percent interest in the Valle de Lerma concession in Northern Argentina. The JV partners are Grasta SA, PetroNEXUS, High Luck Group, and REMSA.

The properties presently held by SAHF are Tartagal Oriental, Morillo, and Valle de Lerma. SAHF is in the process of selling the Tartagal Oriental and Morillo properties. SAHF is not owned by Delta anymore, but as the sale of Tartagal Oriental and Morillo closes, Delta will receive 75 percent of the revenues generated by the transaction. This includes royalties on the production of the properties.

Delta signed an agreement with High Luck for the sale of 18 percent of Tartagal and Morillo. Moreover, the Company signed and executed an agreement for the transfer of 100 percent of its interest in SAHF.

In September of 2017, Delta International Oil & Gas announced that it signed an asset purchase agreement for the acquisition of an oil property in Polk County, Texas from Crestmont Operating, LLC. With the definitive agreement, the Company acquired a 4-well lease in Polk County, estimated to produce 15-20 barrels of oil per day once a workover is completed on one of the wells.

Delta’s domestic oil and gas acquisition strategy commenced in Q2 2017 with a debt/equity investment in a business that is performing rework on gas wells in California. Additionally, it is looking at other opportunities in Texas, Oklahoma, and California to continue its strategy execution.

Furthermore, the Company is prospecting its entry into the water sector. In 2016, it made an initial investment into a water propulsion company.

Delta International Oil & Gas, Inc. (DLTZ), closed Wednesday's trading session at $0.0196, up 10.73%, on 21,000 volume with 3 trades. The average volume for the last 60 days is 18,567 and the stock's 52-week low/high is $0.0155/$0.15.

Cantabio Pharmaceuticals, Inc. (CTBO)

AwesomeStocks, HotStockProfits, Profitable Trading, Leeb’s Market Forecast, OTCtipReporter, PennyStockScholar, Profitable Trader Authority, and Investors Alley reported previously on Cantabio Pharmaceuticals, Inc. (CTBO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Cantabio Pharmaceuticals, Inc. centers on bringing novel, first-in-class drug candidates into clinical trials and beyond. The Company does so via the discovery and development of unique pharmacological chaperone and protein delivery based therapeutics, focusing on protein systems implicated in neurodegenerative disorders. These include Alzheimer’s, Parkinson’s, and oxidative stress. At present, Cantabio Pharmaceuticals is engaging in advanced pre-clinical trials of its therapeutic candidates and is centered on developing these towards clinical trials.

OTCQB-listed, Cantabio Pharmaceuticals, Inc. was created by way of the merger of Gardedam Therapeutics with Cantabio Pharmaceuticals in November 2015. A preclinical stage biotechnology enterprise, Cantabio Pharmaceuticals has its corporate office in Sunnyvale, California.

Cantabio is concentrating on commercializing novel therapies and the Intellectual Property (IP) produced from its research and development (R&D) activities for Parkinson’s disease (PD), Alzheimer’s disease (AD), and other related neurodegenerative diseases. Its strategy mixes a detailed therapeutic emphasis, target family biophysics, and drug discovery technology and expertise into an inventive drug discovery approach.

This particular approach is currently identifying and developing small molecule pharmacological chaperones for clinical trials. In addition, the Company is developing therapeutic proteins, which can pass through the blood-brain barrier to supplement existing levels of proteins that display loss of function during disease conditions.

Cantabio Pharmaceuticals has a new preclinical therapeutic program for Alzheimer’s disease, which it is pursuing via its drug discovery partnership with NovAliX. This program is targeted at the development of small molecule chaperones that stabilize the Abeta peptide, the aggregation of which is considered to be a vital element in the onset and progression of Alzheimer’s disease.

In September 2017, Cantabio Pharmaceuticals announced a publication lead authored by Chief Executive Officer, Dr. Gergely Tóth, along with collaborators at the Hungarian Academy of Sciences and Hungarian Brain Research Program, in the peer-reviewed journal Biochimica et Biophysica Acta - General Subjects.

The article, Structural features of human DJ-1 in distinct Cys106 oxidative states and their relevance to its loss of function in disease, investigated a structure and biophysics-based mechanism by which the DJ-1 protein may lose its neuroprotective function due to high oxidative stress conditions that are present in brain cells of patients with neurodegenerative diseases such as AD and PD.

Recently, Cantabio Pharmaceuticals announced that Dr. Gergely Toth will present results of the Company’s DJ-1 protein targeting small molecule pharmacological chaperone therapeutic program at the Advances in Alzheimer's and Parkinson's Therapies, An AAT-AD/PD Focus Meeting in Torino, Italy, March 15 - 18, 2018.
The data will be presented on March 18, 8:50-9:10 CET - Symposium 27 - Emerging Treatments in PD; Abstract Number AAT18-0226.

Cantabio Pharmaceuticals, Inc. (CTBO), closed Wednesday's trading session at $0.08, up 11.11%, on 100,450 volume with 15 trades. The average volume for the last 60 days is 81,796 and the stock's 52-week low/high is $0.01/$0.27.

Heliospectra AB (publ) (HLSPY)

Barchart, Equities, MarketWatch and OTC Markets reported on Heliospectra AB (HLSPY), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Heliospectra AB (publ) specializes in intelligent lighting technology for plant research and greenhouse cultivation. The Company designs, develops, manufactures, and sells lighting systems in Sweden and around the world. Heliospectra is a global leader in intelligent lighting technology for horticulture controlled environments. The Company is based in Gothenburg, Sweden.

Heliospectra’s lighting system provides an effective and durable technology for cultivating greenhouse and indoor plants through uniting manifold different groups of versatile Light Emitting Diodes (LEDs) with optics, remote sensing techniques, and a strong heat dissipation solution. The Company provides smarter LED grow lights for commercial greenhouses, indoor grow facilities, and research applications.

Heliospectra’s patented solution enables growers to create customized lighting spectrum recipes. These recipes may be able to shorten a cannabis plant’s flowering cycle and even alter a strain’s balance of active cannabinoids.

The design and engineering of the Company’s highly-engineered Heliospectra Light System is to replace traditional lighting solutions in commercial greenhouse environments. For indoor grow facilities, its patented lighting system enables an operation to grow plants that look and taste better, have a longer shelf life, and increase the overall yield of its operation.

Heliospectra’s LED light systems make it possible to closely control the intensity of light wavelengths and to accurately match the spectrum to a particular plant. The spectral distribution of its systems (400nm to 735nm) is consistent with the action spectrum of photosynthesis and critical photomorphological receptors.

This past November, Heliospectra AB announced it was changing the name of the earlier announced light control software CORTEX to HelioCORE™, effective November 16, 2017. The new control system was introduced in July of 2017. It will be available for commercial sales during this Q1 2018. HelioCORE connects the Company’s LX60 adjustable spectra and LX50 high voltage intelligent LED lighting solutions with sensors and schedule functions for real-time light adjustments.

Furthermore, in November, Heliospectra announced that the Company was ranked the second-fastest growing technology company in Deloitte's prestigious Sweden Technology Fast 50. The Sweden Technology Fast 50 ranking includes public and private companies, large and small, in all areas of technology. The basis of the award is on Revenue growth over the last four years. Heliospectra came second with Revenue growth of 4 643 percent.

Last month, Heliospectra announced an order from a value-added reseller for a customer building a high-performance medicinal cannabis cultivation facility in Eastern Canada. The order for the Heliospectra LX60 intelligent LED lighting solution is valued at USD $651,200.

Heliospectra will demonstrate its intelligent lighting solutions, technical services, and new HelioCORE light control software at the upcoming Fruit Logistica event in hall 8.1 booth #B-16, February 7-9, 2018 in Berlin, Germany.

Heliospectra AB (HLSPY), closed Wednesday's trading session at $0.70, even for the day, on 2,158 volume with 5 trades. The average volume for the last 60 days is 24,766 and the stock's 52-week low/high is $0.3809/$1.20.

CV Sciences, Inc. (CVSI)

Wealth Insider Alert, Market Intelligence Center Alert, StreetAuthority Daily, Wall Street Mover, Damn Good Penny Picks, OTCtipReporter, Penny Picks, PennyStockScholar, Profitable Trader Authority, Promotion Stock Secrets, and Stock Commander reported earlier on CV Sciences, Inc. (CVSI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

CV Sciences, Inc. concentrates on developing and commercializing novel therapeutics employing synthetic Cannabidiol (CBD). A life science company, CV Sciences operates two divisions - Pharmaceuticals and Consumer Products. These divisions are supported by its medical and scientific advisory board, and state-of-the-art production facilities.

The Company formerly went by the name CannaVEST Corp. It changed its corporate name to CV Sciences, Inc. in January of 2016. CV Sciences has main offices and facilities in San Diego, California and Las Vegas, Nevada. Fundamentally, the Company is a top supplier and manufacturer of hemp-derived phytocannabinoids, including CBD oil, and a developer of specialty pharmaceutical therapeutics.

CV Sciences’ Pharmaceutical Division is developing synthetically-formulated cannabidiol-based medicine. It is pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications using cannabidiol as the active pharmaceutical ingredient. The Company has realized promising preclinical results in the development of cannabinoid medicines for the treatment of an assortment of medical conditions.

In December of 2015, CV Sciences acquired CanX, Inc. CanX is a Pre-Clinical drug development company. It is focusing on significant unmet medical needs. CanX’s first drug candidate is CVSI-007. CVSI-007 chewing gum combines CBD and Nicotine. It is patent pending. CVSI-007 is a proprietary chewing gum. It combines synthetic CBD and nicotine to effectively treat smokeless tobacco addiction.

The Company’s Consumer Products Division delivers botanical-based cannabidiol products that enhance quality of life. Each consumer products brand is backed by a formal safety review, an growing body of case reports, and physician’s recommendations.

In addition, CV Sciences manufactures, markets, and sells plant-based CBD products under the PlusCBD brand. This is for an array of market sectors. These include nutraceutical, beauty care, specialty foods, as well as vape.

In November 2017, CV Sciences announced that it was named on Deloitte’s Technology Fast 500™. This is a yearly ranking of the fastest growing companies in the technology, media, telecommunications, life sciences and energy technology sectors in North America.

The Deloitte Technology Fast 500 is based on percentage of revenue growth from fiscal year 2013 to 2016, with CV Sciences increasing by 403 percent during this time. 2017 is CV Sciences’ first year named on the Deloitte's Technology Fast 500™ list.

CV Sciences, Inc. (CVSI), closed Wednesday's trading session at $0.3997, up 4.64%, on 510,670 volume with 179 trades. The average volume for the last 60 days is 900,728 and the stock's 52-week low/high is $0.136/$0.68.

Future Farm Technologies, Inc. (FFRMF)

InvestorsHub, MarketWatch, Stockhouse, Morningstar, Barchart, Weed Newswire, OTC Markets, MarketNewsUpdates, and 4-Traders reported on Future Farm Technologies, Inc. (FFRMF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Future Farm Technologies, Inc.’s business model includes developing and acquiring technologies, which will position the Company as a leader in the development of Controlled Environment Agriculture (CEA) for the worldwide production of different kinds of plants, with an emphasis on cannabis. The Company has projects throughout North America. This includes California, Florida, and Maryland.

Established in 1984, Future Farm Technologies is headquartered in Vancouver, British Columbia. The Company lists on the OTC Markets Group’s OTCQB. It previously went by the name Arcturus Growthstar Technologies, Inc. It changed its name to Future Farm Technologies, Inc. in February of 2017. The Company has its U.S. office in Dedham, MA.

Future Farm Technologies is quickly becoming a foremost indoor plant growth technology company specializing in LED lighting and vertical farming solutions. The Company provides scalable, indoor CEA systems that use minimal land, water and energy regardless of climate, location or time of year. These systems are customized to grow an abundance of crops close to consumers.

In addition, Future Farm Technologies holds an exclusive global license to use a patented vertical farming technology that, when compared to traditional plant production methods, produces yields up to 10 times greater per square foot of land. Moreover, the Company employs a leading cannabis oil extraction technology that enables it to process 20lbs/hour of cannabis plant to yield roughly 908 grams/hour of oil.

Furthermore, Future Farm Technologies designs and distributes LED lighting solutions using the COB and MCOB technology. The Company has advanced e-commerce sites that it owns and operates. Its LEDCanada.com caters to B2B customers. It is a supplier of the newest and highest demand LED solutions. Its COBGrowlights.com caters to small and large agriculture green houses and controlled cultivation centers.

Future Farm Technologies recently acquired the exclusive right to use a patented, augmented reality (AR) technology in the cannabis industry. It will work with its partner to merge AR and ad-tech with the cannabis industry via the CannaCube Live™ platform.

Recently, Future Farm Technologies announced that it entered into a definitive agreement with New England CCS to acquire a 51 percent stake in FlipCoin, a new cryptocurrency application and Point of Sale (POS) platform for cannabis dispensaries. The FlipCoin application will permit dispensaries to accept Bitcoin, Ethereum, Bitcoin Cash, or Litecoin as payment.

Last week, Future Farm Technologies announced that it signed a building lease for its Industrial Hemp CBD Oil production and propagation in Maine. The Company announced that it entered into a lease agreement for an initial 12,960 sq. ft. of space in a 60,000 sq. ft. building, with an option to expand and/or purchase the building.

Additionally, last week, Future Farm Technologies announced that it closed on the purchase of a 15,000-sq. ft. building in Providence, Rhode Island. This building is in an M-1 zone that legally allows the cultivation of cannabis by right. Future Farm Technologies’ intention is to lease this property to a local, licensed cultivator who will use the property as a licensed medical marijuana cultivation space, providing wholesale cannabis to Rhode Island's state-sanctioned dispensaries.

Future Farm Technologies, Inc. (FFRMF), closed Wednesday's trading session at $0.7772, up 5.03%, on 1,194,957 volume with 891 trades. The average volume for the last 60 days is 1,483,196 and the stock's 52-week low/high is $0.0996/$1.6598.

Naturally Splendid Enterprises Ltd. (NSPDF)

Stockwatch, Penny Stock Tweets, OTC Markets, InvestorsHub, Stockhouse, MarketWatch, Investing News, DailyMarijuanaObserver, 4-Traders, and Capital Cube reported on Naturally Splendid Enterprises Ltd. (NSPDF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Based in Pitt Meadows, British Columbia, Naturally Splendid Enterprises Ltd. is a purveyor of hemp and plant-based ingredients. The Company is working to be a foremost provider of high quality plant-based functional foods and ingredients. A biotechnology and consumer products business, Naturally Splendid Enterprises is developing, producing, commercializing, and licensing a completely new generation of plant-derived, bioactive ingredients, nutrient dense foods, and related products. The Company lists on the OTCQB.

Naturally Splendid Enterprises has four divisions. These are: Biotechnology, Consumer Products, NATERA® Ingredients - bulk ingredients including HempOmega™, and Co-Packaging/Toll-Processing. HempOmega is a homogenous powder created from microencapsulated, 100 percent Canadian hemp seed oil.

The Company’s hemp and plant based retail product brands are NATERA Hemp Foods, PawsitiveFX, and CHII. These were created to service the diverse ways that consumers can benefit from hemp and other plant based ingredients.

Natera Ingredients is the Company’s wholesale ingredients division. It specializes in hemp and plant based ingredients that are internationally and ethically sourced and processed in Canada in state-of-the-art bio-sciences and dedicated hemp processing facilities in Saskatoon, Saskatchewan.

PawsitiveFX is an all natural pet care retail line. Its commitment is to providing high quality pet products that are healthy, effective, and environmentally sustainable.

CHII (Chi Hemp Industries Incorporated) is a limited liability corporation. It was acquired by Naturally Splendid Enterprises in 2015. Since its incorporation in 1998, CHII has been growing, supplying, facilitating, as well as diversifying the commercial hemp industry.

Naturally Splendid Enterprises’ Bio-Tech sector specializes in using the exceptional science behind hemp and similar plant super foods to, via industry breakthroughs, create a range of nutraceutical and pharmaceutical solutions.

Furthermore, Naturally Splendid Enterprises has its POS-BPC Facility. This is a 12,000-square-foot production facility leased and operated by POS BPC Manufacturing, Inc., a company jointly owned by Naturally Splendid Enterprises (51 percent) and POS Holdings (49 percent). The POS-BPC Facility offers commercial-scale custom processing solutions for functional foods and natural health.

Last month, Naturally Splendid Enterprises announced that Mr. Doug Mason accepted the position of Interim Chief Executive Officer. He replaces Mr. Dave Eto, who moved to the Company’s Advisory Board. Mr. Mason has greater than 25 years of experience in the public markets. He has served as a senior officer and Director for several public companies.

Yesterday, Naturally Splendid Enterprises announced that Cannabis Compliance, Inc. has been retained to prepare the submission for the Company to become a Licensed Dealer of cannabis extracts under the Canadian regulatory regime. Becoming a Licensed Dealer permits Naturally Splendid Enterprises to pursue several activities related to cannabis and the extraction, formulation and distribution of cannabinoids, including cannabidiol (CBD).

Naturally Splendid Enterprises Ltd. (NSPDF), closed Wednesday's trading session at $0.2446, down 0.16%, on 142,190 volume with 41 trades. The average volume for the last 60 days is 114,822 and the stock's 52-week low/high is $0.1081/$0.4195.

Newgioco Group, Inc. (NWGI)

TradingView, OTC Markets, MarketWatch, and LAST10K reported on Newgioco Group, Inc. (NWGI), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Newgioco Group, Inc. is a betting software technology enterprise. It provides regulated leisure lottery and gaming products and services by way of licensed subsidiaries based in Europe. The Company, together with its wholly-owned subsidiaries, is a fully-licensed and integrated gaming software technology enterprise. Newgioco Group has its headquarters in Toronto, Ontario. It also has an office in Rome, Italy.

Newgioco Group conducts its business primarily through retail neighborhood betting shops and an internet-based gambling and sports betting software platform under the registered brand Newgioco, via its licensed website www.newgioco.it located in Italy.

Newgioco has acquired Multigioco Srl. This is a licensed gaming operator based in Rome. Newgioco Group’s plan is to aggressively go after attractively priced, fragmented, and profitable gaming operators in Italy. The Company’s objective is to become a top tier gaming operator over a five-year investment time horizon.

Newgioco provides its clients a complete set of leisure gaming products and services. These include sports betting, virtual sports, online casino, poker, bingo, lottery, interactive games and slots, and an inventive betting platform providing Business-to-Business (B2B) and Business-to-Consumer (B2C) bet processing.

Newgioco Group announced this past July that it obtained certification on its betting software platform required by the Italian gaming authority, the Agency of Customs and Monopolies (ADM). By attaining this internationally recognized ADM Certification, the Company stated that it has demonstrated its commitment to the highest level of security standards and continuous improvement in betting software development, implementation, and also oversight.

Newgioco Group announced this past August the successful launch of its new Betting Platform Technology colloquially named "ELYS." The ELYS software platform went live on August 1, 2017. As a result, sports betting operations are now processed in-house through ELYS. Skill games, lottery, casino, poker, and other entertainment products will continue through the Company’s relationship with Microgame SpA.

Recently, Newgioco Group announced the signing of a major online casino book of business processing roughly $1 million in yearly betting revenue. This reflects immediate benefits from the Company’s newly launched betting technology platform "ELYS."

Newgioco also recently announced the launch of its new mobile betting application on its ELYS betting platform. This new mobile app is dedicated to improving the sport-bet user experience, with casino and poker brands being rolled out this month.

Newgioco Group has a diversified holding of 1,000 internet-based and 120 land-based retail outlets. The model is further diversified across software services offered to B2B and B2C businesses.

Newgioco’s growth is also confirmed by a rise in Gross Gaming Revenue (GGR) of greater than 48 percent in 2016. Current estimates project GGR to more than double by the end of this year. The Company has cash reserves increasing from $1.68 million to $3.19 million.

Newgioco Group, Inc. (NWGI), closed Wednesday's trading session at $0.62, up 3.33%, on 15,666 volume with 8 trades. The average volume for the last 60 days is 23,875 and the stock's 52-week low/high is $0.085/$0.9499.

Rise Gold Corp. (RYES)

StockChase, MarketWatch, Marketwired, Stockhouse, 4-Traders, OTC Markets, and Streetwise Reports reported on Rise Gold Corp. (RYES), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Rise Gold Corp. is an exploration-stage mining company listed on the OTC Markets Group’s OTCQB. The Company’s main asset is the historic past producing Idaho-Maryland Gold Mine located in the State of California. The Idaho-Maryland Mine was a significant past producer, yielding 2.4M oz of gold. Rise Gold has its head office in Vancouver, British Columbia.

There are manifold exploration targets today on the Idaho-Maryland Gold Mine property that is fully owned by Rise Gold. This includes surface and mineral rights. The Company owns all the mineral rights and there are no royalties on this private land. This Mine is near Grass Valley, California.

The Idaho-Maryland Gold Mine produced a total of 2,414,000 oz gold with an average mill head grade of 0.50oz/ton (approximately 17g/t). The Mine was producing up to 129,000 oz gold annually before being forced to shut down by the U.S. government in 1942. During WW II the U.S. War effort wanted to shut down precious metals excavation and shift the national mining workforce from gold to copper production.

This past September, Rise Gold announced that it negotiated an extension of the remaining payment due for the purchase of the 82-acre parcel of M-1 Industrial land neighboring the historic New Brunswick mine shaft in Nevada County, California. The extension of the payment terms will allow Rise Gold to center its financial resources on the exploration drill program at the Idaho-Maryland Gold Project.

The Mill Site property is directly adjacent to the Brunswick Mine shaft. This is where Rise Gold currently owns 37 acres of surface land. The Company’s belief is that the land purchase is a valuable addition to the Idaho-Maryland Gold Project.

In October, Rise Gold announced that exploration core drilling from surface began at the Idaho-Maryland Gold Project in Nevada County, California. The initial exploration drill hole was collared and cased to bedrock. Moreover, the rock core is now being logged.

The initial drill hole will drill through the Brunswick "Porphyrite" Block. It ends in the surrounding serpentinite that hosts the Idaho mineralization. The expectation is that the first hole will pierce several Brunswick style gold-quartz veins and stock-work zones.

Rise Gold Corp. (RYES), closed Wednesday's trading session at $0.1025, up 2.50%, on 47,400 volume with 3 trades. The average volume for the last 60 days is 70,422 and the stock's 52-week low/high is $0.0915/$0.28.


The QualityStocks
Company Corner


Epazz, Inc. (EPAZ)

The QualityStocks Daily Newsletter would like to spotlight Epazz, Inc. (EPAZ). Today, Epazz, Inc. closed trading at $0.13, up 23.81%, on 728,313 volume with 129 trades. The stock’s average daily volume over the past 60 days is 950,728, and its 52-week low/high is $0.0045/$0.52.

Epazz, Inc. (EPAZ) announced today that the company’s ZenaPay Bitcoin wallet has been downloaded more than 20,000 times since its launch in the Android Play Store. Also today, NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, announced the publication of an editorial featuring Epazz. To view the full publication, titled “Blockchain Innovations Create New Synergies,” visit: LINK

Epazz, Inc. (EPAZ), is a leading provider of blockchain cryptocurrency mobile apps and cloud-based business software solutions that specializes in providing customized web applications to the corporate world, higher education institutions and the public sector. The company's strategic expansion into the investment fintech software space can be seen in the recent acquisition of the android app CryptoFolio, which securely tracks and manages Bitcoin and Altcoin portfolios. Epazz, Inc., which acquired the software rights, source code and user base of CryptoFolio, plans to add additional cryptocurrencies and languages to the app, along with an iOS version to attract more users.

Epazz also offers ZenaPay Bitcoin wallet, which has been downloaded more than 10,000 times since its launch on the Play Store. A subsidiary of Epazz, ZenaPay is a financial technology company that offers a unique, secure and reliable Bitcoin payment app, allowing consumers to acquire Bitcoin at the point-of-sale. The consumer can then use this digital currency to make a purchase with ease. The CryptoFolio business model provides free features to attract users and then allows users to purchase additional features from $1.99 to $5.99 each. CryptoFolio is a great add-on app for ZenaPay, and future versions of CryptoFolio will include an option to download ZenaPay.

"We are starting 2018 with ZenaPay on both major mobile apps' platforms," said Shaun Passley, PhD, CEO and founder of Epazz. "We are in the processing of developing new blockchain technology which will introduce an additional source of revenue streams for our company."

Epazz technology makes it easy to convert legacy systems into cloud business process software, for which the company then charges an annual subscription fee. Epazz has acquired 11 software companies that have converted or are in the process of converting their legacy software products to cloud software using Epazz technology. Epazz then markets the new cloud-based solutions to new and existing customers.

Epazz's unique BoxesOS™ applications can create virtual communities for enhanced communication, provide information and content for decision-making, and create a secure marketplace for any type of commerce. Epazz has also filed a provisional patent for its new blockchain smart legal contract technology that reduces fraud in business transactional contracts. The technology allows for a transactional contract to become a living contract that is tracked and traced; it also verifies that a section of terms within a contract are followed and that all parties of an agreement obey the terms of the contract.

"Blockchain-based technology is the future of the Internet," Passley said. "Epazz will add blockchain technology to all of our products in the coming months using our blockchain cloud platform, BoxesOS. The company has been working with customers to understand the best uses of blockchain, and we are excited about filing the first of many blockchain patents, with many more to come." Disclaimer

Epazz, Inc. Company Blog

Epazz, Inc. News:

Epazz ZenaPay Blockchain Wallet Will Support LiteCoin and SegWit in Future Releases; ZenaPay Has Been Downloaded More than 20,000 Times

NetworkNewsWire Announces Publication on Integrating the Power of Blockchain

Blockchain Innovations Create New Synergies

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $1.60, up 15.94%, on 754,302 volume with 1,145 trades. The stock’s average daily volume over the past 60 days is 506,488 and its 52-week low/high is $0.27/$2.54.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announced the publication of an editorial featuring Lexaria Bioscience Corp. (LXRP), a client of NNW that has developed and out-licenses its disruptive patented technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. To view the full publication, titled “Cannabis Deals Cross the Billion-Dollar Mark in Canada,” visit: LINK.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

NetworkNewsWire Announces Publication on Canadian Cannabis Billions Finding Way to Innovators

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Agreement to Create Cannabis-infused Edibles Utilizing DehydraTECH™ Delivery Technology

Cannabis Deals Cross the Billion-Dollar Mark in Canada


The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO). Today, EVIO, Inc. closed trading at $1.66, up 11.41%, on 156,257 volume with 189 trades. The stock’s average daily volume over the past 60 days is 117,973, and its 52-week low/high is $0.47/$2.70.

EVIO, Inc. (EVIO) announced today that it Florida Licensee, Kaycha Holdings LLC d/b/a EVIO Labs Florida has attained ISO 17025 accreditation and becomes the first accredited cannabis testing lab in the state.

EVIO, Inc. (EVIO), via the EVIO Labs division, is the nation's leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation's cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation's leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today's fastest growing industry. Disclaimer

EVIO, Inc. Company Blog

EVIO, Inc. News:

EVIO Labs Florida Licensee Announces ISO 17025 Accreditation

EVIO, Inc. (EVIO) is Exceeding Expectations

NetworkNewsBreaks – EVIO, Inc. (EVIO) Secures Over $5.9M in New Financing to Fund Expansion

MGX Minerals Inc. (MGXMF)

The QualityStocks Daily Newsletter would like to spotlight MGX Minerals Inc. (MGXMF). Today, MGX Minerals Inc. closed trading at $1.1732, up 4.66%, on 239,681 volume with 188 trades. The stock’s average daily volume over the past 60 days is 282,477 and its 52-week low/high is $0.543/$1.5835.

MGX Minerals Inc. (CSE:XMG) (FKT:1MG) (OTCQB:MGXMF) is pleased to announce that 100% wholly-owned subsidiary ZincNyx Energy Solutions, Inc. (“ZincNyx”) has received notice of publication of its patent describing metal-air fuel cells under the Patent Cooperation Treaty (PCT/CA2016/051080).

MGX Minerals Inc. (CSE: XMG) (FKT: 1MG) (OTCQB: MGXMF) is a diversified Canadian resource company developing large-scale mineral portfolios in specific commodities and jurisdictions in North America. The company controls significant interest in lithium, magnesium and silicon assets that offer streamlined development timelines and low capital expenditures. MGX Minerals and its engineering partner have developed a patent-pending, low-energy design process to extract valuable minerals from the abundant, highly mineralized brine wastewater produced each year by oil and gas companies.

This proprietary, petrolithium process rapidly concentrates lithium and other minerals from brine in less than a day. That's a stunning advancement from the conventional method of extracting minerals from brine through an evaporation process that can take up to 18 months, requires hundreds of acres of land, and averages less than a 50 percent mineral recovery rate. Using this advanced water purification technology, MGX Minerals cleans the wastewater that accompanies petroleum as it's being pulled up to the surface. The company's petrolithium process eliminates the need to inject contaminated wastewater back into the ground, which prevents drinking water contamination and possible earthquakes.

In January 2017, MGX Minerals successfully recovered concentrated lithium from heavy oil evaporator blowdown wastewater using its rapid recovery process, an accomplishment independently confirmed by the Saskatchewan Research Council. In August 2017, the company also successfully processed wastewater and lithium brine from eight North American projects at its one-cubic-meter-per-hour processing plant, proving the technology is economically viable. Research group Global Water Intelligence expects the wastewater treatment industry to grow into a $45 billion market annually by 2025, which suggests there are ample revenue-generating opportunities for MGX Minerals technology.

Lithium, the "white gold" of the new energy economy, is the key to clean energy development as global demand for hybrid and electric vehicles, high-drain portable electronic devices, and large-scale energy storage systems ramps up. Grand View Research, Inc. reports that the global lithium-ion battery market is expected to reach $93.1 billion by 2025. Current market forces show a high demand for lithium and a low supply, which further supports the necessity of MGX Mineral's cleaner, faster method of extracting high-value minerals from brine wastewater.

MGX Minerals is led by a team of industry standout performers who have worked in the mining and technology industries for decades. The leadership team is joined by an array of top-notch technical partners with unmatched experience in the oil and gas sectors, environmental services industry, marketing and product development, along with applied research and commercial development of technologies. Disclaimer

MGX Minerals Inc. Blog

MGX Minerals Inc. News:

MGX Minerals Announces Publication and International Filing of Metal-Air Fuel Cell Patent; Eyes Mobile and Marine Applications

MGX Minerals Announces Acquisition of 20 Patents for Zinc Air Fuel Cell Battery

MGX Minerals Receives Approval to Conduct 3D Seismic Survey at Utah Petrolithium Project, Blueberry Unit, Paradox Basin

Petroteq Energy Inc. (TSX.V:PQE) (OTCQX:PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF). Today, Petroteq Energy Inc. closed trading at $1.1036, up 8.20%, on 49,024 volume with 64 trades. The stock’s average daily volume over the past 60 days is 102,136, and its 52-week low/high is $0.015/$1.8892.

Petroteq Energy Inc. (TSX.V:PQE) (OTCQX:PQEFF) today announced significant progress in the assembly of its heavy oil extraction and processing facility in Asphalt Ridge, Utah. Also today, NetworkNewsWire issued a report on the company noting that Petroteq Energy, which was recently approved as a government contractor for the State of Utah, has integrated blockchain into its operations and poised to take advantage of blockchain’s impact on the oil and gas market, as well as infrastructure.

Petroteq Energy Inc. (TSX.V: PQE) (OTCQB: PQEFF), with headquarters in Canada, seeks to create the world's largest pure-play cobalt exploration and development company. The company's current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.

The merger agreements with Cobalt One Ltd. and CobalTech Mining Inc., announced earlier this year, will result in a combined land position of more than 10,000 hectares (nearly 25,000 acres) in the Cobalt Camp containing approximately 50 past cobalt/silver producers and working mines. Initial test results from a mineralogical assessment of sample material taken from various historical mines located throughout the Cobalt Camp show both cobalt-rich and silver-rich mineralization styles. Samples taken at the former Bellellen mine, located within the Greater Cobalt Project in Ontario, show high grade cobalt assays, prompting First Cobalt to increase its drilling program at that site.

Petroteq Energy Inc. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world's current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

The company's clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, Petroteq Energy Inc. and its mining interests are primed for success.

Petroteq Energy Inc. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

Petroteq Energy Inc. Company Blog

Petroteq Energy Inc. News:

Petroteq Energy Announces Progress in Plant Assembly

Blockchain’s Developing Role in American Infrastructure

Blockchain Patents Filings on the Rise, Innovators take the Lead

IEG Holdings Corp. (IEGH)

The QualityStocks Daily Newsletter would like to spotlight IEG Holdings Corp. (IEGH). Today, IEG Holdings Corp. closed trading at $0.305, up 2.35%, on 52,600 volume with 14 trades. The stock’s average daily volume over the past 60 days is 91,829 and its 52-week low/high is $0.14/$5.00.

IEG Holdings Corp. (OTCQB:IEGH), a publicly traded, global leader in consumer finance providing small-sized online personal loans in the United States via a state-licensed operating subsidiary, Investment Evolution Corporation, under the consumer brand “Mr. Amazing Loans,” announces that it has engaged the corporate communications expertise of NetworkNewsWire.

IEG Holdings Corp. (IEGH) is a publicly traded, global leader in consumer finance providing small-sized online personal loans in the United States via a state-licensed operating subsidiary, Investment Evolution Corporation, under the consumer brand "Mr. Amazing Loans." Based in Las Vegas, the company originates consumer loans in 20 states: Alabama, Arizona, California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Missouri, Nevada, New Jersey, New Mexico, Ohio, Oregon, Pennsylvania, Texas, Utah, Virginia and Wisconsin via its online platform and distribution network. IEGH is a licensed direct lender with state licenses and/or certificates of authority to lend in each state and offers all loans within the prevailing statutory rates.

Mr. Amazing Loans is a leading FinTech company specializing in dedicated loan amounts of $5,000 to $10,000 offered directly to consumers through an easy-to-use website known for its professional interaction with applicants. All loans are originated, processed and serviced out of the company's Las Vegas corporate offices, eliminating the need for physical locations in each state where IEGH is licensed to conduct business. The company's loans are unsecured consumer loans that mature in five years at interest rates significantly less than those of payday lenders. Consumers are able to receive same-day processing and are assured of no hidden or additional fees, no prepayment penalty, with repayment and interest rates fixed at 29.9% or less Annual Percentage Rate (APR) for the life of the loan.

The Center for Responsible Lending states the typical payday loan has rates ranging from 391% to 521% APR on loans that typically range from $100 to $1,000. Conversely, Mr. Amazing Loans's terms are designed with low fixed repayments to fit into consumer budgets with the added goal of helping clients reach a stronger financial position. Loan funds are deposited directly into an approved consumer's checking account and may be approved the same day after necessary application documentation is received.

IEG Holdings has also incorporated Investment Evolution Crypto, LLC., a 100 percent owned subsidiary, and tasked the new company with exploring business opportunities in the cryptocurrency/blockchain industry. Specifically, the subsidiary company will explore the legalities and economic risks of entering into a joint venture with IEGH's other 100 percent owned subsidiary company, Investment Evolution Corporation dba Mr. Amazing Loans. Among the questions to be answered during this development planning stage are whether Mr. Amazing Loans should accept repayment of customer loans in the form of leading crypto/blockchain currencies such as Bitcoin, provide the equivalent of USD $5,000 and $10,000 loans to consumers in cryptocurrencies, and potentially create and issue an Investment Evolution cryptocurrency.

Paul Mathieson, IEG Holdings' chairman and Chief Executive Officer, has over 19 years of finance industry experience in lending, funds management, stock market research and investment banking. He has been a member of the board of directors at IEGH since 2012 and of its subsidiary since 2009. Mathieson founded IEG Holdings Limited in Sydney, Australia, launching the Amazing Loans business in that country in 2005 and then in the United States via IEGC in 2010. He was awarded Ernst & Young's 2007 Australian Young Entrepreneur of the Year (Eastern Region). Mathieson is joined by Carla Cholewinski, who serves as chief operating officer with over 37 years of experience in the finance industry including banking, credit union management, regulatory oversight, debt securitization and underwriting. Disclaimer

IEG Holdings Corp. Blog

IEG Holdings Corp. News:

IEG Holdings Corp. (IEGH) Engages NetworkNewsWire for Corporate Communications Solutions

IEG Holdings Corp. (IEGH) Aims to be Key Player in the Cryptocurrency/Blockchain Sector

NetworkNewsBreaks – IEG Holdings Corp. (IEGH) Intends to Create Cryptocurrency Backed by Gold Metal

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF). Today, PreveCeutical Medical Inc. closed trading at $0.35, up 0.40%, on 26,309 volume with 15 trades. The stock’s average daily volume over the past 60 days is 7,226, and its 52-week low/high is $0.01/$0.80.

Hydrogels have been in limited commercial use for more than two decades. However, advancements in drug delivery, and thus hydrogel technology, are driving rapid growth in the global market, which is now projected to surge to over $22 billion by 2022 with a compound annual growth rate (CAGR) of 6.3 percent (http://nnw.fm/GWv2x), according to BCC Research. In what may prove to be a groundbreaking approach in this field of exponential opportunity, PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is engineering a unique sol-gel nose-to-brain drug delivery platform to provide clinical relief of multiple physical maladies.

PreveCeutical Medical Inc. (PRVCF), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word "PreveCeutical" – a combination of the words "preventive" and "pharmaceutical" – was a precursor to the company's formation and incorporation in October 2015.

The company's first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical's research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical's gene-silencing technology would effectively "turn off" the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical's science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland's (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.'s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company's core. Disclaimer

PreveCeutical Medical Inc. Company Blog

PreveCeutical Medical Inc. News:

Investment Opportunities in Advanced Bioengineered Drug Delivery

PreveCeutical Medical Inc. (PRVCF) Engages NetworkNewsWire for Corporate Communications Solutions

NetworkNewsAudio Announces Audio Press Release (APR) on Exciting New Solutions to Tackle Pain

Veritas Pharma, Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP)

The QualityStocks Daily Newsletter would like to spotlight Veritas Pharma, Inc. (VRTHF). Today, Veritas Pharma, Inc. closed trading at $0.4319, up 9.70%, on 106,066 volume with 57 trades. The stock’s average daily volume over the past 60 days is 284,642 and its 52-week low/high is $0.22/$0.881.

Veritas Pharma, Inc. (CSE: VRT) (OTCQB: VRTHF) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas' R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma's goal is to perform clinical trials to prove the efficacy of the designated lead cannabis strains and to market the clinically effective cultivars as prescription medicines in a fast-track protocol.

Veritas Pharma's management and R&D team comprises decades of pharmaceutical, clinical and scientific research expertise into several key industry leaders. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry, leads the company as its CEO. In addition to a team of trained technicians and students working out of academic facilities, Veritas Pharma is pleased to have a renowned group of scientists on board to lead its research efforts. Team members hold 10 PhDs/MD licenses with expertise in chemistry, pharmacology and clinical trials.

Veritas Pharma's mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company's approach, combined with its strategic alliances, will effectively address the medical community's concerns over the complexities of cannabis potency, efficacy, quality and content in the nearly 800 marijuana strains currently known in the world. Opportunities for innovation and scientific advancement related to the field of cannabis therapeutics will accelerate the knowledge base and provide a valuable alternative to the global opioid market that is estimated at nearly U.S. $35 billion. A growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as those provided by cannabis.

Veritas Pharma's clinical cannabis development pipeline includes R&D for chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder. The strategic alliance formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants, which they plan to patent protect for a variety of unmet medical needs, are destined to help patients suffering with chronic and debilitating symptoms of a variety of medical issues. Over 250 experiments have been performed so far with another 150 pharmacological and biological studies conducted. Veritas Pharma has also entered into an agreement with Sechelt Organic Marijuana Inc., which has a Licensed Producer application pending with Health Canada, to acquire 100 percent ownership in the company.

Results of the company's research to date illustrate Veritas' unique place in the medical marijuana industry. The company's focus on the biological effect of the actual spectrum of cannabinoids sets Veritas apart as it seeks to patent and protect results-driven strains. Disclaimer

Veritas Pharma, Inc. Blog

Veritas Pharma, Inc. News:

Veritas’ Research Arm Cannevert Signs Clinical Research Agreement for Human Studies to Assess its Lead Cannabis Strain for Pain

Veritas Pharma Provides Comment on U.S. Attorney General Jeff Sessions Memo

Veritas Pharma Provides Year End Update on Company’s Activities to Shareholders

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.9722, up 4.54%, on 1,616,862 volume with 950 trades. The stock’s average daily volume over the past 60 days is 1,831,805, and its 52-week low/high is $0.177/$1.95.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Closes Over-Subscribed C$9.4 Million Financing

CannabisNewsWire Announces Publication on Increased Investment Activity in Cannabis

CannabisNewsWire Announces Publication on Influx of Capital Ahead of Expanded Cannabis Legalization in North America


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Daily Trade Alert
(SNAP) +47.58%


(BSPM) +26.79%


MarketClub Analysis
(MODN) +26.55%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251